Federal Register #FDA-2025-N-7395

FDA Debarment Order for Felony Drug Conviction – No Procurement Involved

This notice announces a regulatory enforcement action by the Food and Drug Administration (FDA) against Dr. Naveed Aslam, following his felony conviction for illegal prescription drug sales. - Government Buyer: - Food and Drug Administration (FDA), Department of Health and Human Services - OEMs and Vendors Mentioned: - Cancer drug manufacturers referenced: Enhertu, Padcev, Poteligo, Tivdak, Trodelvy - Products/Services Requested: - No products or services are being procured or requested - Unique or Notable Requirements: - Permanent debarment of Dr. Naveed Aslam from participating in any activities related to drug product applications - Entities employing Dr. Aslam during the debarment may face civil money penalties - Action is based on conviction for illegal purchase and resale of prescription cancer drugs - No procurement or award activity; this is strictly a legal and regulatory action

Description

The Food and Drug Administration (FDA) is issuing a final order permanently debarring Naveed Aslam from providing services in any capacity to a person with an approved or pending drug product application. This action follows Dr. Aslam's conviction of a felony under Federal law related to drug regulation, specifically for the illegal sale or trade of prescription drugs. Dr. Aslam was notified of the proposed debarment and given an opportunity to request a hearing but did not respond, thereby waiving his right to a hearing. The debarment is effective as of September 25, 2026, and any use of Dr. Aslam's services during this period may result in civil money penalties.

View original listing